Medical Director, Endocrinology
Vertex Pharmaceuticals - Boston, MA
Posted Oct 30, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Offered From the posting source checked Nov 17, 2026
- Verification
- Not verified
- Salary
- $240K-$360K From the posting source checked Nov 17, 2026
- 401(k) match
- Not verified
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $81,444 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +6.9% - Faster than average
268% above the BLS role benchmark for healthcare aggregate.
Posted salary is far from this role benchmark; treat it as low confidence.
Matched to SOC 29-1141 - Healthcare aggregate by role bucket.
Source:U.S. Bureau of Labor Statistics, OEWS, May 2024andEmployment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 17, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Medical Director, Endocrinology Boston, MA Job Description Vertex completed its acquisition of Crinetics Pharmaceuticals on September 1, adding commercial and pipeline endocrinology programs to Vertex's innovation portfolio. The acquisition is expected to accelerate revenue growth and enhance the Company's long-term earnings profile. The acquired portfolio includes PALSONIFY® (paltusotine), atumelnant, and several additional pipeline programs. PALSONIFY is the first and only once-daily oral therapy for acromegaly; it has launched in the United States, is approved in the European Union, and is under review by other global regulatory authorities. Atumelnant is an investigational, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH) and Phase 2 development for Cushing's syndrome. We are seeking a pediatric or adult endocrinologist to contribute clinical expertise to the development of atumelnant. The Clinical Development Medical Director will serve as the Medical Lead for Vertex clinical trials, working with cross-functional multidisciplinary study teams on clinical trial strategy, design and execution and serving as the Medical Monitor responsible for monitoring the safety of enrolled subjects on assigned trials. The incumbent will work on multiple trials in all Phases of clinical development, and may also participate in other selected projects in clinical development. Key Duties and Responsibilities: Leads the development of Study Protocols, Investigator Brochures, Clinical Development Plans and other key study documents in conjunction with other line functions and with minimal guidance Serves on cross-functional Study Execution Teams (SET) for assigned trials, working with other team members to achieve efficient, high-quality study
Read the full description at vrtx.wd501.myworkdayjobs.com. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Publications Science Director, Endocrinology
Vertex Pharmaceuticals - Boston, MA
Director, Clinical Business Operations
Rapport Therapeutics Inc - 99 High Street, Suite 2100 , Boston, MA 02110
Director, Clinical Sciences
Amylyx Pharmaceuticals Inc - Cambridge, MA
Medical Director, Clinical Research Neuromuscular
Cytokinetics Inc - South San Francisco, California